ATOSSA THERAPEUTICS, INC. — Form 8-K
Filed August 7, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 42/100
What the filing says
Atossa Therapeutics completed a registered direct offering issuing 1,363,637 common shares and two warrant series (each for 1,363,637 shares) for $4.5M gross upfront proceeds, with up to $12M additional if warrants are fully exercised, totaling potential $16.5M. The company reported Q2 2026 net loss of $8.5M (vs. $8.4M in Q2 2025) and cash of $26.1M as of June 30, 2026 (down from $41.3M Dec 31, 2025). Lead candidate (Z)-endoxifen advanced with completed enrollment in Phase 2 EVANGELINE breast cancer trial and peer-reviewed publications in rare disease (DMD, McCune-Albright Syndrome) and oncology applications.
Why this rating
Capital raise of $4.5M–$16.5M equals 4–15% of $107M market cap; meaningful but not transformational. Cash burn of ~$18.6M for H1 2026 implies ~14 months runway at current burn rate, partially offset by financing. Clinical progress is early-stage without readout catalysts disclosed. Warrant dilution present but typical for biotech.
See more from August 7, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.